Neuroblastoma - Pipeline Review, H1 2018

  • ID: 4564090
  • Drug Pipelines
  • 543 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Actuate Therapeutics Inc
  • Biotec Pharmacon ASA
  • Cleveland BioLabs Inc
  • GlaxoSmithKline Plc
  • MediaPharma SRL
  • Ribomic Inc
  • MORE
Neuroblastoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H1 2018, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights:

This latest pipeline guide Neuroblastoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 30, 15, 3, 44, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 14 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actuate Therapeutics Inc
  • Biotec Pharmacon ASA
  • Cleveland BioLabs Inc
  • GlaxoSmithKline Plc
  • MediaPharma SRL
  • Ribomic Inc
  • MORE
Introduction

Neuroblastoma - Overview

Neuroblastoma - Therapeutics Development

Neuroblastoma - Therapeutics Assessment

Neuroblastoma - Companies Involved in Therapeutics Development

Neuroblastoma - Drug Profiles

Neuroblastoma - Dormant Projects

Neuroblastoma - Discontinued Products

Neuroblastoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Neuroblastoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H1 2018

Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H1 2018

Neuroblastoma - Pipeline by Alissa Pharma, H1 2018

Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H1 2018

Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2018

Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2018

Neuroblastoma - Pipeline by Autolus Ltd, H1 2018

Neuroblastoma - Pipeline by Bayer AG, H1 2018

Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H1 2018

Neuroblastoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018

Neuroblastoma - Pipeline by BioLineRx Ltd, H1 2018

Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H1 2018

Neuroblastoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Neuroblastoma - Pipeline by Bristol-Myers Squibb Co, H1 2018

Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2018

Neuroblastoma - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2018

Neuroblastoma - Pipeline by Cebiotex SL, H1 2018

Neuroblastoma - Pipeline by Celgene Corp, H1 2018

Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H1 2018

Neuroblastoma - Pipeline by Cellectar Biosciences Inc, H1 2018

Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H1 2018

Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H1 2018

Neuroblastoma - Pipeline by CorMedix Inc, H1 2018

Neuroblastoma - Pipeline by Curis Inc, H1 2018

Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018

Neuroblastoma - Pipeline by DEKK-TEC Inc, H1 2018

Neuroblastoma - Pipeline by EnGeneIC Ltd, H1 2018

Neuroblastoma - Pipeline by Epizyme Inc, H1 2018

Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H1 2018

Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Neuroblastoma - Pipeline by GC Pharma, H1 2018

Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H1 2018

Neuroblastoma - Pipeline by ID Pharma Co Ltd, H1 2018

Neuroblastoma - Pipeline by Ignyta Inc, H1 2018

Neuroblastoma - Pipeline by Ipsen SA, H1 2018

Neuroblastoma - Pipeline by Juno Therapeutics Inc, H1 2018

Neuroblastoma - Pipeline by Kazia Therapeutics Ltd, H1 2018

Neuroblastoma - Pipeline by Loxo Oncology Inc, H1 2018

Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H1 2018

Neuroblastoma - Pipeline by MacroGenics Inc, H1 2018

Neuroblastoma - Pipeline by MediaPharma SRL, H1 2018

Neuroblastoma - Pipeline by Merck & Co Inc, H1 2018

Neuroblastoma - Pipeline by Morphogenesis Inc, H1 2018

Neuroblastoma - Pipeline by Novartis AG, H1 2018

Neuroblastoma - Pipeline by OGD2 Pharma SAS, H1 2018

Neuroblastoma - Pipeline by Pfizer Inc, H1 2018

Neuroblastoma - Pipeline by Phylogica Ltd, H1 2018

Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2018

Neuroblastoma - Pipeline by Recombio SL, H1 2018

Neuroblastoma - Pipeline by Ribomic Inc, H1 2018

Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H1 2018

Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2018

Neuroblastoma - Pipeline by Sierra Oncology Inc, H1 2018

Neuroblastoma - Pipeline by Sorrento Therapeutics Inc, H1 2018

Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H1 2018

Neuroblastoma - Pipeline by TheraBiologics Inc, H1 2018

Neuroblastoma - Pipeline by Trellis Bioscience Inc, H1 2018

Neuroblastoma - Pipeline by ZIOPHARM Oncology Inc, H1 2018

Neuroblastoma - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Neuroblastoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ability Pharmaceuticals SL
  • Actuate Therapeutics Inc
  • Alissa Pharma
  • Ampio Pharmaceuticals Inc
  • APEIRON Biologics AG
  • AstraZeneca Plc
  • Autolus Ltd
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • Bexion Pharmaceuticals LLC
  • Bio-Cancer Treatment International Ltd
  • BioLineRx Ltd
  • Biotec Pharmacon ASA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cancer Prevention Pharmaceuticals Inc
  • Cancer Therapeutics CRC Pty Ltd
  • Cebiotex SL
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Cielo Therapeutics Inc
  • Cleveland BioLabs Inc
  • CorMedix Inc
  • Curis Inc
  • Cyclacel Pharmaceuticals Inc
  • DEKK-TEC Inc
  • EnGeneIC Ltd
  • Epizyme Inc
  • Errant Gene Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • GC Pharma
  • GlaxoSmithKline Plc
  • ID Pharma Co Ltd
  • Ignyta Inc
  • Ipsen SA
  • Juno Therapeutics Inc
  • Kazia Therapeutics Ltd
  • Loxo Oncology Inc
  • MabVax Therapeutics Holdings Inc
  • MacroGenics Inc
  • MediaPharma SRL
  • Merck & Co Inc
  • Morphogenesis Inc
  • Novartis AG
  • OGD2 Pharma SAS
  • Pfizer Inc
  • Phylogica Ltd
  • Progenics Pharmaceuticals Inc
  • Recombio SL
  • Ribomic Inc
  • Sapience Therapeutics Inc
  • Sareum Holdings Plc
  • Sierra Oncology Inc
  • Sorrento Therapeutics Inc
  • Syros Pharmaceuticals Inc
  • TheraBiologics Inc
  • Trellis Bioscience Inc
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll